A.


Start adjuvant treatment
[1st line]
Routine surveillance
RPD
< 1 year
RPD
>1 year
RPD
</> 1 year
Start 2nd line
[advanced]
Local treatment
Start 1st line
[advanced]
Start 3rd line
[advanced]
Best supportive care
[death]
Start 2nd line
[advanced]
Start 3rd line
[advanced]

B.

	Adjuvant treatment [1st line]						Adjuvant treatment [1st line]		Routine surveillance
	RPD < 1 year						**RPD > 1 year**		**RPD </> 1 year**
	Pembrolizumab/Nivolumab				Dabrafenib-trametinib		Any adjuvant treatment / Routine surveillance		
	NICE guidelines		*Owen et al (2020)*		*Leeneman et al (2020)*		*Leeneman et al (2020)*		
Line of treatment	**2nd line**	**3rd line**	**2nd line**	**3rd line**	**2nd line**	**3rd line**	**1st line**	**2nd line**	**3rd line**
Systemic treatment (%)	**100**	**32.6**	**100**	**32.6**	**100**	**48.0**	**83.7**	**39.8**	**17.4**
Pembrolizumab	-	-	-	-	40.0	19.1	20.0	8.7	4.0
Ipilimumab	50.3	20.4	15.0	6.1	22.0	10.9	11.6	10.3	2.3
Nivolumab	-	-	-	-	20.0	9.5	10.4	4.7	1.6
Nivolumab + Ipilimumab	-	-	37.0	15.1	18.0	8.5	9.2	5.9	1.2
Dabrafenib-trametinib	49.7	12.2	48.0	12.4	-	-	32.5	10.2	8.3
No systemic treatment	-	*67.4*	-	*67.4*	-	*52.0*	*16.3*	*60.2*	*82.6*
Total	*100%*	*100%*	*100%*	*100%*	*100%*	*100%*	*100%*	*100%*	*100%*